Gilead Sciences : GILD

All Gilead Sciences Articles

734 Articles

Paul Ausick | Jan 23, 2017 at 4:04 PM EST

Teva, Gilead Sciences Tumble into Monday’s 52-Week Low Club

DryShips, Teva, Endo Pharma, and Gilead Sciences posted new 52-week lows Monday.

Lee Jackson | Jan 23, 2017 at 9:55 AM EST

Jefferies Has Cheap Biotech and Pharma Stocks to Buy for 2017

A new Jefferies research report makes the case that while market parameters are indeed expensive, there still are cheap stocks…

Chris Lange | Jan 12, 2017 at 9:35 AM EST

Biotech Short Sellers Run for Cover

As we have approached Trump’s inauguration, the health care sector in general has rallied. Now it’s time to see what…

Lee Jackson | Jan 10, 2017 at 8:35 AM EST

Jefferies Has 5 Top Biotech Stocks to Buy for 2017

Needless to say, the past two years have been rough on biotech. The question for investors is which of the…

Chris Lange | Dec 28, 2016 at 10:10 AM EST

Biotech Short Interest Sinks

The December 15 short interest data have been compared with the previous report, and short interest was down in most…

Chris Lange | Dec 12, 2016 at 9:10 AM EST

Biotech Short Interest Remains Mixed

The November 30 short interest data have been compared with the previous report, and short interest was mixed in the…

Paul Ausick | Dec 8, 2016 at 4:04 PM EST

FitBit, Gilead Sciences in Thursday’s 52-Week Low Club

December 8, 2016: Here are four stocks trading with relatively heavy volume among 34 equities making new 52-week lows in…

Chris Lange | Nov 28, 2016 at 7:35 AM EST

Short Sellers Grow More Aggressive on Major Biotechs

The November 15 short interest data have been compared with the previous report, and short interest increased in most of…

Jon C. Ogg | Nov 10, 2016 at 1:26 PM EST

Gilead Scores Another Hepatitis FDA Approval

Gilead Sciences has announced that the FDA has approved its once-a-day treatment for adults with chronic hepatitis B virus infection.

Chris Lange | Nov 10, 2016 at 7:20 AM EST

Short Sellers Grow More Selective on Major Biotechs

Now that the U.S. presidential election is over and Hillary Clinton is out of the picture, major biotech companies can…

Jon C. Ogg | Nov 6, 2016 at 10:20 AM EST

How Analysts View Value and Opportunity in Gilead After Earnings

If you just looked at formal Buy and Sell ratings from Wall Street analysts, you might assume that everything is…

Chris Lange | Nov 1, 2016 at 4:58 PM EDT

Has Gilead Finally Bottomed?

Gilead Sciences Inc. (NASDAQ: GILD) released third-quarter earnings report after markets closed on Tuesday. Despite negative news coming out on…

Chris Lange | Nov 1, 2016 at 11:15 AM EDT

What to Expect From Gilead Earnings

Although Gilead has been falling for about a year now, the valuation is looking more favorable — assuming Gilead is…

Chris Lange | Oct 30, 2016 at 10:05 AM EDT

8 Top Earnings for the Week Ahead

24/7 Wall St. has put together a preview of Pfizer, Starbucks and some of the major companies reporting their quarterly…

Chris Lange | Oct 26, 2016 at 7:15 AM EDT

Short Sellers Can’t Make Up Their Minds on Major Biotechs

The October 14 short interest data have been compared with the previous report, and short interest moves in these selected…

1 … 22 23 24 25 26 … 49

Gilead Sciences : GILD

All Gilead Sciences Articles

Teva, Gilead Sciences Tumble into Monday’s 52-Week Low Club

Jefferies Has Cheap Biotech and Pharma Stocks to Buy for 2017

Biotech Short Sellers Run for Cover

Jefferies Has 5 Top Biotech Stocks to Buy for 2017

Biotech Short Interest Sinks

Biotech Short Interest Remains Mixed

FitBit, Gilead Sciences in Thursday’s 52-Week Low Club

Short Sellers Grow More Aggressive on Major Biotechs

Gilead Scores Another Hepatitis FDA Approval

Short Sellers Grow More Selective on Major Biotechs

How Analysts View Value and Opportunity in Gilead After Earnings

Has Gilead Finally Bottomed?

What to Expect From Gilead Earnings

8 Top Earnings for the Week Ahead

Short Sellers Can’t Make Up Their Minds on Major Biotechs

Why Americans Are Quietly Retiring to Greece at 62 on $2,800 a Month

Common Debt Payoff Strategies Compared

5 Under the Radar AI Chip Stocks Powering the Data Center Boom

Why Americans Are Quietly Retiring to Greece at 62 on $2,800 a Month

Medicare Won't Touch Long-Term Care. The Average Nursing-Home Year Runs Past $100,000.

Why Americans Are Quietly Retiring to Greece at 62 on $2,800 a Month

Common Debt Payoff Strategies Compared

Gilead Sciences : GILD

All Gilead Sciences Articles

Teva, Gilead Sciences Tumble into Monday’s 52-Week Low Club

Jefferies Has Cheap Biotech and Pharma Stocks to Buy for 2017

Biotech Short Sellers Run for Cover

Jefferies Has 5 Top Biotech Stocks to Buy for 2017

Biotech Short Interest Sinks

Biotech Short Interest Remains Mixed

FitBit, Gilead Sciences in Thursday’s 52-Week Low Club

Short Sellers Grow More Aggressive on Major Biotechs

Gilead Scores Another Hepatitis FDA Approval

Short Sellers Grow More Selective on Major Biotechs

How Analysts View Value and Opportunity in Gilead After Earnings

Has Gilead Finally Bottomed?

What to Expect From Gilead Earnings

8 Top Earnings for the Week Ahead

Short Sellers Can’t Make Up Their Minds on Major Biotechs

Why Americans Are Quietly Retiring to Greece at 62 on $2,800 a Month

Common Debt Payoff Strategies Compared

5 Under the Radar AI Chip Stocks Powering the Data Center Boom

Featured Reads

Why Americans Are Quietly Retiring to Greece at 62 on $2,800 a Month

Medicare Won't Touch Long-Term Care. The Average Nursing-Home Year Runs Past $100,000.